-
Something wrong with this record ?
Deubiquitinases (DUBs) and DUB inhibitors: a patent review
P. Farshi, RR. Deshmukh, JO. Nwankwo, RT. Arkwright, B. Cvek, J. Liu, QP. Dou,
Language English Country England, Great Britain
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- MeSH
- Drug Resistance, Neoplasm MeSH
- Molecular Targeted Therapy MeSH
- Proteasome Inhibitors pharmacology MeSH
- Humans MeSH
- Neoplasms drug therapy enzymology MeSH
- Patents as Topic MeSH
- Antineoplastic Agents pharmacology MeSH
- Drug Design MeSH
- Ubiquitin-Specific Proteases antagonists & inhibitors metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, N.I.H., Extramural MeSH
INTRODUCTION: Deubiquitinating-enzymes (DUBs) are key components of the ubiquitin-proteasome system (UPS). The fundamental role of DUBs is specific removal of ubiquitin from substrates. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. Altered DUB activity is associated with a multitudes of pathologies including cancer. Therefore, DUBs represent novel candidates for target-directed drug development. AREAS COVERED: The article is a thorough review/accounting of patented compounds targeting DUBs and stratifying/classifying the patented compounds based on: chemical-structures, nucleic-acid compositions, modes-of-action, and targeting sites. The review provides a brief background on the UPS and the involvement of DUBs. Furthermore, methods for assessing efficacy and potential pharmacological utility of DUB inhibitor (DUBi) are discussed. EXPERT OPINION: The FDA's approval of the 20S proteasome inhibitors (PIs): bortezomib and carfilzomib for treatment of hematological malignancies established the UPS as an anti-cancer target. Unfortunately, many patients are inherently resistant or develop resistance to PIs. One potential strategy to combat PI resistance is targeting upstream components of the UPS such as DUBs. DUBs represent a promising potential therapeutic target due to their critical roles in various cellular processes including protein turnover, localization and cellular homeostasis. While considerable efforts have been undertaken to develop DUB modulators, significant advancements are necessary to move DUBis into the clinic.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020673
- 003
- CZ-PrNML
- 005
- 20160727102651.0
- 007
- ta
- 008
- 160722s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1517/13543776.2015.1056737 $2 doi
- 024 7_
- $a 10.1517/13543776.2015.1056737 $2 doi
- 035 __
- $a (PubMed)26077642
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Farshi, Pershang $u a 1 Wayne State University, Barbara Ann Karmanos Cancer Institute, School of Medicine , Detroit, Michigan, USA doup@karmanos.org.
- 245 10
- $a Deubiquitinases (DUBs) and DUB inhibitors: a patent review / $c P. Farshi, RR. Deshmukh, JO. Nwankwo, RT. Arkwright, B. Cvek, J. Liu, QP. Dou,
- 520 9_
- $a INTRODUCTION: Deubiquitinating-enzymes (DUBs) are key components of the ubiquitin-proteasome system (UPS). The fundamental role of DUBs is specific removal of ubiquitin from substrates. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. Altered DUB activity is associated with a multitudes of pathologies including cancer. Therefore, DUBs represent novel candidates for target-directed drug development. AREAS COVERED: The article is a thorough review/accounting of patented compounds targeting DUBs and stratifying/classifying the patented compounds based on: chemical-structures, nucleic-acid compositions, modes-of-action, and targeting sites. The review provides a brief background on the UPS and the involvement of DUBs. Furthermore, methods for assessing efficacy and potential pharmacological utility of DUB inhibitor (DUBi) are discussed. EXPERT OPINION: The FDA's approval of the 20S proteasome inhibitors (PIs): bortezomib and carfilzomib for treatment of hematological malignancies established the UPS as an anti-cancer target. Unfortunately, many patients are inherently resistant or develop resistance to PIs. One potential strategy to combat PI resistance is targeting upstream components of the UPS such as DUBs. DUBs represent a promising potential therapeutic target due to their critical roles in various cellular processes including protein turnover, localization and cellular homeostasis. While considerable efforts have been undertaken to develop DUB modulators, significant advancements are necessary to move DUBis into the clinic.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a nádory $x farmakoterapie $x enzymologie $7 D009369
- 650 _2
- $a patenty jako téma $7 D010330
- 650 _2
- $a inhibitory proteasomu $x farmakologie $7 D061988
- 650 _2
- $a specifické proteázy ubikvitinu $x antagonisté a inhibitory $x metabolismus $7 D064570
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Deshmukh, Rahul R $u a 1 Wayne State University, Barbara Ann Karmanos Cancer Institute, School of Medicine , Detroit, Michigan, USA doup@karmanos.org. b 2 Wayne State University, Department of Pathology, School of Medicine , Detroit, Michigan, USA.
- 700 1_
- $a Nwankwo, Joseph O $u c 3 Federal University Ndufu-Alike Ikwo, Faculty of Basic Medical Sciences, Department of Medical Biochemistry , Ebonyi State, Nigeria.
- 700 1_
- $a Arkwright, Richard T $u a 1 Wayne State University, Barbara Ann Karmanos Cancer Institute, School of Medicine , Detroit, Michigan, USA doup@karmanos.org. d 4 Wayne State University, Department of Oncology, School of Medicine , Detroit, Michigan, USA. $7 gn_A_00008536
- 700 1_
- $a Cvek, Boris $u e 5 Palacky University, Department of Cell Biology & Genetics , Slechtitelu 11, Olomouc 78371, Czech Republic.
- 700 1_
- $a Liu, Jinbao $u f 6 Guangzhou Medical University, State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Department of Pathophysiology , Guangdong 510182, China.
- 700 1_
- $a Dou, Q Ping $u a 1 Wayne State University, Barbara Ann Karmanos Cancer Institute, School of Medicine , Detroit, Michigan, USA doup@karmanos.org. b 2 Wayne State University, Department of Pathology, School of Medicine , Detroit, Michigan, USA. d 4 Wayne State University, Department of Oncology, School of Medicine , Detroit, Michigan, USA. g 7 Wayne State University, Department of Pharmacology, School of Medicine , Detroit, Michigan, USA.
- 773 0_
- $w MED00181402 $t Expert opinion on therapeutic patents $x 1744-7674 $g Roč. 25, č. 10 (2015), s. 1191-208
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26077642 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160727102912 $b ABA008
- 999 __
- $a ok $b bmc $g 1155343 $s 945201
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 25 $c 10 $d 1191-208 $e 20150616 $i 1744-7674 $m Expert opinion on therapeutic patents $n Expert Opin Ther Pat $x MED00181402
- LZP __
- $a Pubmed-20160722
